Etrasimod (VELSIPITY™): A Comprehensive Pharmacological and Clinical Review for Ulcerative Colitis

1. Introduction to Etrasimod (VELSIPITY™)

1.1. Overview and Therapeutic Class

Etrasimod, marketed under the brand name VELSIPITY™, is an orally administered small molecule medication.[1] It is identified by DrugBank ID DB14766 and CAS Number 1206123-37-6.[1] Etrasimod is classified as a synthetic, next-generation selective sphingosine-1-phosphate (S1P) receptor modulator.[4] This agent was initially discovered by Arena Pharmaceuticals, with subsequent development undertaken by Pfizer.[1]

1.2. Approved Indication (Ulcerative Colitis)

Etrasimod is primarily indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adult populations.[1] In certain jurisdictions, such as the European Union and Canada, this indication is extended to include patients 16 years of age and older who have demonstrated an inadequate response, experienced a loss of response, or were intolerant to either conventional therapy or an advanced treatment modality, such as a biologic agent or a Janus kinase (JAK) inhibitor.[3]

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease (IBD) characterized by diffuse mucosal inflammation predominantly affecting the colon and rectum. The clinical manifestations of UC are burdensome and include persistent diarrhea, often with blood and mucus, abdominal pain, rectal urgency, and systemic symptoms such as fatigue and weight loss.[8]

The approval of etrasimod for patients who have previously failed or are intolerant to conventional therapies, biologics, or JAK inhibitors positions it as a significant therapeutic advancement. The management of UC often follows a step-up approach, where patients may cycle through various treatments due to primary non-response, secondary loss of response, or intolerance.[3] Many advanced therapies, particularly biologics, require parenteral administration. The availability of an effective oral agent like etrasimod, which offers a distinct mechanism of action, addresses a critical unmet need for convenience and an alternative therapeutic strategy for individuals with difficult-to-treat UC.[3] This may potentially delay or obviate the need for colectomy in some patients.[3]

The designation of etrasimod as a "next-generation" S1P receptor modulator [4] suggests pharmacological refinements compared to earlier agents in this class. These improvements are likely related to enhanced receptor selectivity and potentially an optimized safety or pharmacokinetic profile. For instance, older S1P modulators such as fingolimod and ozanimod are associated with specific monitoring requirements (e.g., first-dose observation for bradycardia due to effects on S1P3 receptors) and exhibit broader S1P receptor activity. Etrasimod's specific selectivity for S1P receptor subtypes 1, 4, and 5, with minimal activity on S1P3 and no activity on S1P2, and its lack of a requirement for dose titration [3], are highlighted as potential advantages. This suggests a targeted development strategy aimed at improving the benefit-risk profile within the S1P modulator class.

2. Pharmacology of Etrasimod

2.1. Mechanism of Action (S1P Receptor Modulation)

Etrasimod functions as a selective sphingosine-1-phosphate (S1P) receptor modulator, exhibiting high-affinity binding to S1P receptor subtypes 1, 4, and 5 (S1P1, S1P4, S1P5).[1] Its activity on S1P3 receptors is minimal (reportedly 25-fold lower than the maximum plasma concentration (Cmax​) at the recommended dose), and it demonstrates no detectable activity on S1P2 receptors.[2] Pharmacologically, etrasimod acts as an agonist at S1PR1 and as a partial agonist at S1PR4 and S1PR5.[2]

The binding of etrasimod to S1P receptors located on lymphocytes, particularly T cells, partially and reversibly inhibits their egress from secondary lymphoid organs, such as lymph nodes.[1] This sequestration of lymphocytes leads to a dose-dependent reduction in the number of circulating peripheral lymphocytes.[2] While the precise mechanism by which etrasimod exerts its therapeutic effects in ulcerative colitis remains to be fully elucidated, it is hypothesized to involve the diminished migration of these pro-inflammatory lymphocytes into the inflamed intestinal mucosa.[1] Elevated expression of S1PR1 has been observed in colonic biopsies from UC patients, associated with increased intestinal vascularization at inflamed sites, a characteristic feature of UC-related inflammation.[2]

2.2. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion)

Etrasimod is administered orally and is rapidly absorbed.[1] The US prescribing information indicates that etrasimod can be taken with or without food.[10] However, regulatory bodies in Europe (EMA) and the UK (MHRA) recommend taking etrasimod with food for the first three days of treatment, likely to mitigate the potential for first-dose bradycardic effects by slowing absorption and blunting peak plasma concentrations.[16] This difference reflects varying regional approaches to managing the known class effect of S1P modulators on heart rate upon initiation.

Etrasimod exhibits high plasma protein binding, at approximately 97.9%.[1] This high degree of protein binding suggests that the free, pharmacologically active fraction of the drug is low, a common characteristic factored into dosing, and also implies that the amount excreted into breast milk is likely to be minimal.[4]

The drug undergoes extensive hepatic metabolism.[1] The primary metabolic pathways involve oxidation and dehydrogenation, predominantly mediated by cytochrome P450 (CYP) enzymes CYP2C8, CYP2C9, and CYP3A4, with minor contributions from CYP2C19 and CYP2J2.[6] Etrasimod also undergoes conjugation, mainly via UDP-glucuronosyltransferases (UGTs), with a minor role for sulfotransferases.[6] Importantly, etrasimod metabolism results in the parent compound and non-active minor metabolites, with no major pharmacologically active metabolites discovered.[3] This lack of active metabolites simplifies pharmacokinetic modeling and reduces potential inter-patient variability in drug response due to differing metabolite activities.

The elimination half-life of etrasimod is approximately 30 hours, supporting a once-daily dosing regimen.[1] Excretion occurs primarily through feces (82%) and to a lesser extent via the kidneys (5%).[1]

No clinically significant differences in pharmacokinetics have been observed based on gender, age, or body weight, thus precluding the need for weight-based dose adjustments, although caution is advised for patients weighing less than 40 kg.[3] Etrasimod use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C), while no dosage adjustment is necessary for those with mild to moderate hepatic impairment.[10] Increased etrasimod exposure is anticipated in individuals who are CYP2C9 poor metabolizers, particularly with concomitant use of moderate to strong inhibitors of CYP2C8 or CYP3A4; such co-administration is not recommended.[10]

The combination of once-daily oral dosing, a half-life conducive to this regimen, and the absence of major active metabolites contributes to a predictable pharmacokinetic profile and enhances patient convenience and adherence, crucial aspects for managing a chronic condition like UC.

Table 1: Key Pharmacokinetic Parameters of Etrasimod

Parameter	Value / Description	Source(s)
Administration Route	Oral	1
Food Effect	US: With or without food. EU/UK: With food for first 3 days.	10
Plasma Protein Binding	97.9%	1
Metabolism	Hepatic: Oxidation & dehydrogenation (CYP2C8, CYP2C9, CYP3A4 primarily; minor CYP2C19, CYP2J2). Conjugation (UGTs primarily; minor sulfotransferases).	1
Active Metabolites	No major pharmacologically active metabolites	3
Elimination Half-Life	Approximately 30 hours	1
Primary Excretion Route	Feces (82%), Kidneys (5%)	1

2.3. Pharmacodynamics (Effects on Lymphocyte Counts)

Consistent with its mechanism of action, etrasimod induces a dose-dependent reduction in peripheral blood lymphocyte counts.[2] Clinical data indicate a mean reduction in lymphocyte counts ranging from 43% to 55% of baseline values over a 52-week period.[22] Other reports specify a reduction to approximately half of their baseline value by 2 weeks of treatment, an effect that is maintained throughout the duration of therapy.[2] This effect is reported to be more pronounced on adaptive immune cells, which are strongly implicated in the pathogenesis of UC, while having a minimal impact on innate immune cells that are crucial for general immunosurveillance.[2]

A key pharmacodynamic feature of etrasimod is the reversibility of its effect on lymphocyte counts. Following discontinuation of VELSIPITY™, lymphocyte counts generally return to normal within 4 to 5 weeks.[10] This targeted reduction of adaptive lymphocytes, coupled with the relative sparing of innate immunity and the reversibility of lymphocyte depletion, suggests a potentially favorable balance between achieving therapeutic efficacy in UC and maintaining essential immune defense mechanisms. The capacity for immune reconstitution upon drug cessation is an important safety attribute, distinguishing it from some therapies with more prolonged immunosuppressive effects, and allows for flexibility in clinical management should the drug need to be stopped due to adverse events or other clinical considerations.

3. Clinical Efficacy in Ulcerative Colitis

3.1. Overview of the ELEVATE UC Clinical Trial Program (ELEVATE UC 52 & ELEVATE UC 12)

The regulatory approvals for etrasimod by the FDA and other international agencies were primarily supported by data from the ELEVATE UC Phase 3 registrational program. This program comprised two pivotal, randomized, double-blind, placebo-controlled trials: ELEVATE UC 52 and ELEVATE UC 12.[8] These trials were designed to evaluate the efficacy and safety of etrasimod administered at a dose of 2 mg once daily in patients with moderately to severely active UC who had previously experienced an inadequate response to, loss of response to, or intolerance to at least one conventional therapy, biologic agent, or JAK inhibitor.[8]

ELEVATE UC 52 was a 52-week study, incorporating a 12-week induction phase followed by a 40-week maintenance phase, utilizing a treat-through design wherein all enrolled patients were included in the efficacy evaluation at the end of the 40-week maintenance period without re-randomization of responders.[14] In this trial, 289 patients were randomized to receive etrasimod, and 144 patients were randomized to receive placebo.[29] ELEVATE UC 12 was a 12-week induction trial [7], in which 238 patients were assigned to etrasimod and 116 to placebo.[29] The FDA approval was based on data from a total of 741 patients across these two trials [26], while the MHRA approval documentation cited 743 patients aged 16 years and older.[15]

3.2. Key Efficacy Outcomes

Etrasimod demonstrated statistically significant and clinically meaningful improvements across a spectrum of key efficacy endpoints in both the induction and maintenance phases of the ELEVATE UC program. Achieving not only symptomatic relief but also objective measures of inflammation, such as endoscopic improvement and mucosal healing, is increasingly recognized as crucial for long-term favorable outcomes in UC management. The consistency of etrasimod's efficacy across these varied endpoints and time points reinforces the robustness of the clinical trial findings.

Table 2: Summary of Key Efficacy Results from ELEVATE UC 52 and ELEVATE UC 12 Trials

Endpoint	Trial	Time Point	Etrasimod 2mg (%)	Placebo (%)	P-value / Risk Difference (95% CI)	Source(s)
Clinical Remission	ELEVATE UC 52	Week 12	27.0	7.4	P<0.001; Risk Difference: 19.8% (12.9% to 26.6%)	User Query, 8
	ELEVATE UC 52	Week 52	32.1	6.7	P<0.001; Risk Difference: 25.4% (18.4% to 32.4%)	User Query, 8
	ELEVATE UC 12	Week 12	24.8 (or 26.0)	15.2 (or 15.0)	P=0.0264; Risk Difference: 9.7% (1.1% to 18.2%)	8
Endoscopic Improvement	ELEVATE UC 52	Week 12	28.6 (approx.)	7.4 (approx.)	P<0.001; Risk Difference: 21.2% (13.0% to 29.3%)	14
	ELEVATE UC 52	Week 52	34.8 (approx.)	8.1 (approx.)	P<0.001; Risk Difference: 26.7% (19.0% to 34.4%)	14
	ELEVATE UC 12	Week 12	21.0 (approx.)	8.9 (approx.)	P=0.0092; Risk Difference: 12.1% (3.0% to 21.2%)	14
Mucosal Healing	ELEVATE UC 52	Week 52	26.6 (or 27)	8.1 (or 8)	P<0.001; Risk Difference: 18.4% (11.4% to 25.4%)	14
	ELEVATE UC 12	Week 12	19.3 (approx.)	7.8 (approx.)	P=0.0358	29
Symptomatic Remission	ELEVATE UC 52	Week 12/52	Significantly higher	Lower	P<0.001	29
	ELEVATE UC 12	Week 12	Significantly higher	Lower	P=0.0013	29
Clinical Response	ELEVATE UC 52 & UC 12	Week 12/52	Significantly higher	Lower	P<0.001	29
Sustained Clinical Remission (Wk 12&52)	ELEVATE UC 52	Week 52	17.9	2.2	P<0.001; Risk Difference: 15.8% (10.7% to 21.0%)	14
Corticosteroid-Free Clinical Remission	ELEVATE UC 52	Week 52	32.1	6.7	P<0.001; Risk Difference: 25.4% (18.4% to 32.4%) (overall)	14
	ELEVATE UC 52	Week 52	31.0	7.5	Risk Difference: 23.1% (baseline CS users)	14

Note: Approximate percentages for Endoscopic Improvement and Mucosal Healing (Week 12) are derived from risk differences and placebo rates where direct percentages were not co-located. A meta-analysis incorporating three studies, including an earlier Phase 2 trial, also confirmed the superiority of etrasimod over placebo in achieving clinical remission at week 12, with an odds ratio (OR) of 3.09.[18]

3.3. Long-Term Efficacy and Maintenance of Remission

The ELEVATE UC 52 trial demonstrated sustained efficacy of etrasimod through 52 weeks of treatment.[8] Further insights into long-term outcomes are being gathered from ongoing open-label extension (OLE) studies, namely ELEVATE UC OLE and ES101002 OLE, with cumulative safety and efficacy data reported for up to 4 years of exposure.[30] Additionally, a Matching-Adjusted Indirect Comparison (MAIC) suggested that while induction phase clinical response rates were similar between etrasimod and ozanimod (another S1P receptor modulator), etrasimod might offer improved clinical response and remission outcomes during the maintenance phase.[28]

3.4. Efficacy in Specific Ulcerative Colitis Patient Subgroups

Analysis of subgroups within the ELEVATE UC program provided further insights:

• Biologic/JAKi-naive vs. Experienced Patients: For the endpoint of endoscopic improvement, greater between-group risk differences favoring etrasimod over placebo were observed in patients who were naive to any prior biologic or JAK inhibitor therapy compared to those who were treatment-experienced. Similarly, patients who had received only one prior biologic or JAK inhibitor appeared to derive greater benefit compared to those who had received multiple such agents.[14]
• Monotherapy vs. Concomitant Therapy (Corticosteroids and/or 5-Aminosalicylates): A dedicated analysis revealed that etrasimod monotherapy was effective compared to placebo. Clinical remission rates at Week 12 were 26.2% for etrasimod monotherapy versus 4.8% for placebo monotherapy, and at Week 52, these rates were 35.7% versus 4.0%, respectively.[34] Notably, this analysis suggested no apparent additional benefit from concomitant use of corticosteroids (CS) and/or 5-aminosalicylates (5-ASA) in patients receiving etrasimod.[34] This finding is particularly significant as it indicates that etrasimod's efficacy as a standalone advanced therapy is substantial. It supports the potential for simplifying treatment regimens and reducing patient reliance on corticosteroids, which are associated with considerable long-term adverse effects. The achievement of corticosteroid-free remission in a notable proportion of patients further underscores this potential.[14]

4. Safety Profile and Tolerability

4.1. Common Adverse Reactions

In the clinical trial program for ulcerative colitis, the most frequently reported common adverse reactions (typically defined as incidence ≥5%) with etrasimod included:

• Headache [1]
• Elevated liver function tests [8]
• Dizziness [10]
• Lymphopenia (a very common finding, reported at 11% in some summaries) [9]

Other adverse events reported in the ELEVATE trials included worsening of UC and COVID-19 infection, reflecting background rates in this patient population.[29] The European Medicines Agency (EMA) European Public Assessment Report (EPAR) also lists arthralgia, hypertension, urinary tract infection, nausea, hypercholesterolemia, lower respiratory tract infection, and herpes viral infection as common adverse reactions.[22]

Table 3: Common Adverse Reactions of Etrasimod (Incidence ≥2% and >Placebo in Pooled ELEVATE UC Trials at 52 Weeks)

(Note: Specific pooled data for ≥5% was not uniformly available across all snippets for a direct table matching the outline's request. The Prescribing Information typically provides such a table. The following is based on commonly cited AEs and available data, focusing on those mentioned as common or with percentages.)

Adverse Reaction	Etrasimod 2mg (%) (Approximate/Illustrative)	Placebo (%) (Approximate/Illustrative)	Source(s)
Headache	7	(Varies by trial)	1
Lymphopenia	11	(Lower)	9
Elevated Liver Tests (ALT/AST)	Higher than placebo	Baseline rates	8 (0.9% >3xULN consecutive)
Dizziness	≥5 (as per common AE threshold)	(Varies by trial)	10
Arthralgia	Common	(Varies by trial)	22
Hypertension	Common	(Varies by trial)	22
Urinary Tract Infection	Common	(Varies by trial)	15
Nausea	Common	(Varies by trial)	22
Herpes Viral Infection	Common (0.4% HZ in controlled)	(0.8% HZ in controlled)	22
COVID-19	Reported	Reported	29
Worsening Ulcerative Colitis	Reported	Reported	29

Actual percentages from pivotal trial publications or prescribing information should be consulted for precise figures.

4.2. Serious Adverse Reactions, Warnings, and Precautions

Etrasimod, like other S1P receptor modulators, is associated with several important warnings and precautions that necessitate careful patient selection, pre-treatment screening, and ongoing monitoring.

• Infections: There is an increased risk of infections, some of which can be serious or life-threatening, due to the reduction in peripheral blood lymphocyte count.8 Patients should be monitored for signs and symptoms of infection during treatment and for 5 weeks following discontinuation. Interruption of treatment should be considered if a serious infection develops. An analysis of the ELEVATE program (787 patients) indicated that the proportions and incidence rates of all infection events were similar for patients receiving etrasimod 2 mg once daily (18.8%; incidence rate 41.1 per 100 patient-years [PY]) compared to placebo (17.7%; IR 49.0 per 100 PY). Serious infections occurred in 0.6% of etrasimod-treated patients versus 1.9% of placebo-treated patients. Two herpes zoster events were reported in each group (etrasimod: 0.4%; placebo: 0.8%), all of which were localized and non-serious. One opportunistic infection event was reported in each group. Importantly, no patient with an absolute lymphocyte count (ALC) <0.2×109/L reported serious/severe or opportunistic infections, and no baseline risk factors were identified for such events in this analysis.31
• Progressive Multifocal Leukoencephalopathy (PML): Although rare, PML, a debilitating and potentially fatal opportunistic viral infection of the brain caused by the John Cunningham (JC) virus, has been reported with S1P receptor modulators. Physicians should maintain vigilance for new or worsening neurological symptoms suggestive of PML. Etrasimod should be suspended if PML is suspected and permanently discontinued if confirmed.[10]
• Herpes Viral Infections: Cases of herpes simplex encephalitis, varicella zoster meningitis, and localized herpes viral infections (including ophthalmic) have been reported. Testing for VZV antibodies and vaccination of susceptible patients are recommended prior to initiating etrasimod.[22]
• Cryptococcal Infections: Fatal cryptococcal meningitis and disseminated cryptococcal infections have been reported with S1P receptor modulators. Patients presenting with symptoms consistent with cryptococcal infection should undergo prompt diagnostic evaluation, and etrasimod should be suspended until the infection is excluded or treated.[22]
• Bradyarrhythmia and Atrioventricular (AV) Conduction Delays: Etrasimod may cause a transient decrease in heart rate and AV conduction delays, particularly after the first dose.[8] First-degree and second-degree Mobitz type I AV block have been reported.[22] An ECG is required before initiating treatment, and cardiology consultation should be considered for patients with certain pre-existing cardiac conditions or those taking concomitant medications that slow heart rate or AV conduction.[10] Long-term OLE data (up to 4 years) reported no serious adverse events of bradycardia and no occurrences of second-degree Mobitz type II or third-degree AV block.[30] This is a noteworthy finding, potentially reflecting etrasimod's minimal S1P3 activity, a receptor subtype more strongly implicated in cardiac S1P modulator effects.
• Liver Injury: Elevations of aminotransferases (ALT, AST) may occur.[8] Baseline LFTs are required, and levels should be monitored if symptoms suggestive of hepatic dysfunction arise. In OLE data, 11 patients (0.9%) had ALT levels >3 times the upper limit of normal (ULN) at two consecutive post-baseline visits; however, no cases met Hy's Law criteria (concurrent elevation of ALT/AST >3x ULN and total bilirubin >2x ULN).[30] VELSIPITY should be discontinued if significant liver injury is confirmed.
• Macular Edema: An increased risk of macular edema is associated with S1P receptor modulators. A baseline ophthalmic evaluation of the fundus, including the macula, is required prior to or near the start of treatment, with periodic evaluations as clinically indicated, especially if vision changes occur.[8] In the placebo-controlled UC cohort, the incidence of macular edema was low and comparable between etrasimod (0.3%) and placebo (0.3%).[37] In the "All UC cohort" (including OLE data), cystoid macular edema was reported in 0.1% of patients. Most events were non-serious, and one led to discontinuation.[30]
• Increased Blood Pressure: Blood pressure should be monitored during treatment with VELSIPITY, as increases have been observed.[8] No serious adverse events of hypertension were reported in the long-term OLE data.[30]
• Fetal Risk: Based on animal studies, VELSIPITY may cause fetal harm. Females of reproductive potential must be advised of this risk and counseled on the use of effective contraception during treatment and for one week following discontinuation of VELSIPITY.[8] A pregnancy exposure registry exists to monitor outcomes.
• Cutaneous Malignancies: An increased risk of skin cancers (e.g., basal cell carcinoma, squamous cell carcinoma, melanoma) has been observed with S1P receptor modulators. Skin examinations are recommended prior to or shortly after initiation and periodically thereafter, particularly for patients with known risk factors for skin cancer. Patients should be advised to limit sun exposure and use appropriate sun protection. Any suspicious skin lesions should be promptly evaluated.[8] OLE data reported two cases of squamous cell carcinoma and one case of basal cell carcinoma.[30]
• Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported with drugs in the S1P receptor modulator class. Symptoms may include severe headache, altered mental status, visual disturbances, and seizures. If PRES is suspected, VELSIPITY should be discontinued, and appropriate diagnostic evaluation (e.g., MRI) should be performed.[8]
• Respiratory Effects: A potential decline in pulmonary function (e.g., FEV1, FVC) may occur. Spirometric assessment should be performed if clinically indicated (e.g., new or worsening dyspnea).[10]
• Unintended Additive Immune System Effects: When switching to VELSIPITY from therapies with prolonged immune effects, the half-life and mode of action of the prior drug(s) must be carefully considered to avoid unintended additive immunosuppression.[10]
• Immune System Effects After Discontinuing VELSIPITY: Peripheral lymphocyte counts typically return to the normal range within 4 to 5 weeks after cessation of VELSIPITY. If concomitant immunosuppressants are used during this period, patients should be monitored for infectious complications.[10]

4.3. Overall Safety Assessment

The overall safety profile of etrasimod, derived from clinical trials including long-term extensions up to 4 years (involving 1196 patients with 1619.5 PYs of total exposure), appears manageable when appropriate pre-treatment screening and ongoing monitoring are implemented.[30] Most treatment-emergent adverse events (TEAEs) were non-serious and infrequently led to treatment discontinuation. The incidence of key adverse events of special interest, such as serious infections and herpes zoster, was low and, in controlled settings, often comparable to placebo.[30] The lack of new safety signals with extended exposure is reassuring for its long-term use. Three deaths were reported in the OLE program, all of which were deemed unrelated to etrasimod treatment by investigators.[30]

5. Dosage and Administration

5.1. Recommended Dosing Regimen for Ulcerative Colitis

The recommended dosage of VELSIPITY for the treatment of moderately to severely active ulcerative colitis is 2 mg administered orally once daily.[3] A notable feature of etrasimod is that no dose titration is required upon initiation of therapy, allowing patients to receive the full therapeutic dose from the outset.[3] This simplified regimen can improve patient adherence and ease clinical management compared to some other advanced UC therapies that necessitate up-titration or are administered via injection or infusion.

5.2. Pre-treatment Assessments, Medications, and Vaccinations

A comprehensive set of pre-treatment evaluations is crucial for the safe initiation of etrasimod therapy, reflecting its potent immunomodulatory nature and potential systemic effects. Failure to perform these checks could lead to preventable adverse events.

Table 4: Pre-treatment Assessment and Vaccination Checklist for Etrasimod Therapy

Assessment Category	Specific Test/Action	Rationale/Link to Precaution	Source(s)
Hematologic	Recent Complete Blood Count (CBC) including lymphocyte count (within 6 months or post prior UC therapy)	To establish baseline lymphocyte count; risk of lymphopenia and infections	10
Cardiac	Electrocardiogram (ECG)	To detect pre-existing conduction abnormalities; risk of bradyarrhythmia and AV conduction delays	10
	Cardiology consultation	For patients with certain pre-existing cardiac conditions or on rate-lowering drugs	10
Hepatic	Recent Liver Function Tests (LFTs) - transaminases and bilirubin (within 6 months)	To establish baseline liver function; risk of liver injury	10
Ophthalmic	Baseline evaluation of the fundus, including the macula	To detect pre-existing conditions; risk of macular edema	10
Dermatologic	Skin examination (prior to or shortly after initiation)	To detect pre-existing lesions; risk of cutaneous malignancies	10
Infectious Disease/ Vaccination	VZV antibody testing	For patients without confirmed history of varicella or full VZV vaccination	10
	VZV vaccination	Recommended for antibody-negative patients; postpone VELSIPITY for 4 weeks post-vaccination	10
	Review and update immunizations	Per current guidelines; live attenuated vaccines at least 4 weeks prior to VELSIPITY	9
Medication Review	Current or prior medications	Identify drugs that slow heart rate/AV conduction, or are anti-neoplastic, immune-modulating, or non-corticosteroid immunosuppressants	10

5.3. Administration Instructions and Management of Missed Doses

VELSIPITY tablets should be swallowed whole. According to the US prescribing information, they can be taken with or without food.[10] However, the EMA and MHRA labeling recommend taking the first three doses with food to potentially mitigate the initial bradycardic effect.[16] If a dose of VELSIPITY is missed, the patient should take the missed dose at the next scheduled dosing time; the subsequent dose should not be doubled to make up for the missed dose.[10]

6. Drug Interactions

Etrasimod's metabolic pathway and pharmacodynamic effects predispose it to several clinically significant drug interactions.

6.1. Interactions with CYP Enzyme Inhibitors and Inducers

Etrasimod is primarily metabolized by CYP2C8, CYP2C9, and CYP3A4.[6]

• Moderate to strong inhibitors of both CYP2C9 and CYP3A4 (e.g., fluconazole): Concomitant use is not recommended as it can significantly increase etrasimod exposure and the risk of adverse reactions.[9]
• CYP2C9 Poor Metabolizers also taking moderate to strong inhibitors of CYP2C8 or CYP3A4: Concomitant use is not recommended due to the potential for markedly increased etrasimod exposure.[10]
• Rifampin (a strong CYP inducer): Concomitant use is not recommended because it can substantially decrease etrasimod exposure, potentially reducing its efficacy.[9]
• Abametapir (a CYP3A4 inhibitor): May increase the serum concentration of etrasimod.[6]

The critical role of these CYP enzymes in etrasimod's clearance means that strong modulators of these pathways can have a profound impact on drug exposure, necessitating the specific contraindications or non-recommendations for co-administration with drugs like fluconazole and rifampin.

6.2. Interactions with Heart Rate/Conduction Modifying Drugs

• Anti-Arrhythmic Drugs (Class Ia e.g., quinidine, procainamide; Class III e.g., amiodarone, sotalol) and other QT Prolonging Drugs: Co-administration may increase the risk of QT interval prolongation and Torsades de Pointes. Cardiology consultation is advised before initiating etrasimod in patients taking these medications.[10]
• Beta-Blockers or Calcium Channel Blockers (e.g., verapamil, diltiazem): These drugs can cause additive heart rate reduction when used with etrasimod. Cardiology consultation is advised when initiating beta-blockers or calcium channel blockers in patients on stable VELSIPITY therapy, or when initiating VELSIPITY in patients already receiving these agents.[9]

6.3. Interactions with Immunosuppressive Therapies

• Anti-neoplastic, Immune-modulating, or Non-corticosteroid Immunosuppressive Therapies: Concomitant administration with VELSIPITY should generally be avoided due to the risk of additive immunosuppressive effects and an increased risk of infections.[6] When switching from therapies with prolonged immune effects, their half-life and mode of action must be considered to avoid overlapping immunosuppression. Examples of drugs that may increase the risk or severity of immunosuppression when combined with etrasimod include abatacept, abemaciclib, abiraterone, adalimumab, afatinib, and aldesleukin.[6]

6.4. Vaccines

• Live Attenuated Vaccines: Administration of live attenuated vaccines should occur at least 4 weeks prior to initiating VELSIPITY. Live attenuated vaccines should be avoided during VELSIPITY treatment and for 5 weeks after its discontinuation due to the risk of inducing infection.[9]
• Other Vaccines: The efficacy of other vaccines may be reduced if administered during VELSIPITY treatment.

The potential for additive pharmacodynamic interactions, particularly those affecting cardiac function or immune status, underscores the necessity for a thorough medication review prior to initiating etrasimod and often warrants specialist consultation to ensure patient safety.

Table 5: Clinically Significant Drug Interactions with Etrasimod

Interacting Drug/Class	Potential Effect on Etrasimod or Concomitant Drug	Clinical Recommendation/Management Strategy	Source(s)
CYP2C9 & CYP3A4 Dual Inhibitors (e.g., fluconazole)	Increased etrasimod exposure, increased risk of AEs	Concomitant use not recommended	9
Strong CYP Inducers (e.g., rifampin)	Decreased etrasimod exposure, potential loss of efficacy	Concomitant use not recommended	9
CYP2C9 Poor Metabolizers + CYP2C8 or CYP3A4 Inhibitors	Markedly increased etrasimod exposure	Concomitant use not recommended	10
Anti-Arrhythmics (Class Ia, III), QT Prolonging Drugs	Additive QT prolongation, risk of Torsades de Pointes	Cardiology consultation advised	10
Beta-Blockers, Calcium Channel Blockers	Additive heart rate reduction	Cardiology consultation advised	9
Other Immunosuppressants (anti-neoplastic, immune-modulating)	Additive immunosuppression, increased infection risk	Avoid concomitant use; consider prior therapy effects	6
Live Attenuated Vaccines	Risk of infection from vaccine; reduced vaccine efficacy	Administer ≥4 weeks before VELSIPITY; avoid during and for 5 weeks after VELSIPITY	9

7. Regulatory Approvals and Global Status

Etrasimod (VELSIPITY™) has achieved regulatory approvals in several key regions worldwide for the treatment of ulcerative colitis, reflecting a recognized therapeutic need and a generally positive assessment of its efficacy and safety data by multiple health authorities. This rapid succession of approvals following its initial marketing authorization underscores its potential impact on UC management.

Table 6: Global Regulatory Approval Status of Etrasimod (VELSIPITY™) for Ulcerative Colitis

Regulatory Agency/Region	Approval Date	Specific Indication (Age, Line of Therapy if specified)	Source(s)
FDA (USA)	October 12/13, 2023	Moderately to severely active ulcerative colitis in adults.	User Query, 1
EMA/EC (Europe)	February 2024 (EC Grant) (CHMP Opinion Dec 2023)	Patients ≥16 years with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biological agent.	1
Health Canada (Canada)	April 24, 2024 (NOC)	Adult patients (≥16 years) with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.	12
TGA (Australia)	May 17, 2024 (Approved) October 2024 (PBS Listing)	Ulcerative colitis.	19
Swissmedic (Switzerland)	September 10, 2024	Second-line treatment of adults with moderately to severely active UC. (Authorized via Access Consortium)	19
MHRA (UK)	March 11, 2024	People >16 years with moderately to severely active UC for whom standard treatment or other treatments did not work well enough or could not be used. (Authorized via Access Consortium)	15
Israel Ministry of Health	Approved (Date not specified)	Ulcerative colitis.	40
Macau (Pharmaceutical Administration Bureau)	April 2024	Patients ≥16 years with moderately to severely active UC.	40
Singapore (Health Sciences Authority)	Approved (Date not specified) (Authorized via Access Consortium)	Ulcerative colitis.	13
Hong Kong (Department of Health)	April 2025 (NDA Approval)	Adults with moderately to severely active UC.	44
China (NMPA)	NDA Accepted Dec 2024	Patients with moderately to severely active UC.	44

Regulatory applications for etrasimod in ulcerative colitis have also been submitted to other countries, including India, Mexico, Russia, and Turkey.[9] The involvement of the Access Consortium (a collaboration between regulatory authorities in Australia, Canada, Singapore, Switzerland, and the UK) for some of these approvals likely facilitated more efficient review processes.[19]

A slight variation exists in the approved age range: while the US approval is for "adults," the EU, UK, and Canadian approvals specify "patients 16 years of age and older." This difference likely reflects the specific age data from the ELEVATE trials (which enrolled patients aged 16-80 [21]) considered sufficient by these respective agencies, thereby broadening its applicability in those regions to include older adolescents.

8. Etrasimod in Other Inflammatory Conditions (Brief Overview of Clinical Development)

Beyond its established role in ulcerative colitis, etrasimod has been investigated for a range of other immune-mediated inflammatory diseases, leveraging its mechanism of lymphocyte trafficking modulation. The outcomes of these investigations have been varied, underscoring the complex and distinct pathophysiological roles of S1P receptor modulation and lymphocyte migration in different diseases.[1]

8.1. Crohn's Disease (CD)

Etrasimod is under investigation for CD in the Phase 2/3 CULTIVATE trial (NCT04173273).[37] Data from the extension phase of substudy A (Phase 2), presented at UEGW 2024, indicated favorable efficacy and tolerability in patients with moderately to severely active CD. At 52 weeks, endoscopic response was achieved by 19.5% of patients receiving etrasimod 3 mg and 14.3% of those receiving 2 mg. Clinical remission, as defined by the Crohn's Disease Activity Index (CDAI), was reached by 34.1% (3 mg) and 28.6% (2 mg) of patients, respectively. The 3 mg dose suggested numerically higher efficacy. Further placebo-controlled studies are ongoing to confirm these findings.[43]

8.2. Atopic Dermatitis (AD)

The Phase 2 ADVISE trial (NCT04176588) assessed etrasimod (1 mg and 2 mg daily) versus placebo in adults with moderate-to-severe AD.[37] The primary endpoint, defined as the percent change in Eczema Area and Severity Index (EASI) score from baseline at week 12, was not met for the etrasimod 2 mg group compared to placebo (-57.2% vs. -48.4%, p=0.18).[41] However, the etrasimod 2 mg dose did demonstrate efficacy on several other clinician- and patient-assessed measures. For instance, a significantly greater proportion of patients receiving etrasimod 2 mg achieved a validated Investigator's Global Assessment (vIGA-AD) score of 0 or 1 (clear or almost clear) with a ≥2-point improvement from baseline at Week 12 compared to placebo (29.8% vs. 13.0%; p=0.045). The drug was well tolerated, and the results were deemed to warrant further clinical investigation in AD.[41]

8.3. Eosinophilic Esophagitis (EoE)

In the Phase 2 VOYAGE trial (NCT04682639), etrasimod was evaluated in adults with EoE.[25] The etrasimod 2 mg once-daily dose met the primary endpoint, demonstrating a statistically significant median percentage change from baseline in esophageal peak eosinophil count (PEC) at week 16 (-58.4%) compared to placebo (-21.5%; p=0.010). The 1 mg dose did not meet the primary endpoint (p=0.29).[25] Etrasimod 2 mg also led to sustained histological and endoscopic improvements over 52 weeks, along with symptom improvement in patients without a history of esophageal dilation, and was well tolerated. These findings provide the first evidence that targeting the S1P pathway can ameliorate disease activity in EoE, suggesting S1P receptor modulation as a viable therapeutic target for this condition.[25]

8.4. Alopecia Areata (AA)

A Phase 2 trial (NCT04556734) investigated etrasimod in adults with moderate to severe AA, defined by a Severity of Alopecia Tool (SALT) score of ≥25.[35] The primary endpoint, percent change from baseline in SALT score at Week 24, was not achieved for either etrasimod 2 mg or 3 mg compared to placebo. The least squares mean difference versus placebo was -14.1% for the 2 mg dose (p=0.2579) and -21.8% for the 3 mg dose (p=0.0592).[35] Although numerical improvements in SALT scores were generally higher in the etrasimod groups, the lack of statistical significance led to the discontinuation of the etrasimod clinical program for AA.[42] Etrasimod was reported to be well tolerated in this study, with a safety profile consistent with other etrasimod trials.[42]

The variable success across these different immune-mediated diseases suggests that while reducing lymphocyte migration via S1P1,4,5 modulation is effective in conditions like UC and shows promise in EoE and potentially CD, the specific contribution of these lymphocytes or the overall disease mechanisms in other conditions like AA, and to a lesser extent AD, may be less responsive to this particular therapeutic approach or may require different dosing strategies. Dose-response relationships also appear to be an important consideration, with higher doses (e.g., 3mg in CD) or specific doses (2mg in EoE) showing more promise than lower doses in some investigational settings.

9. Conclusion and Future Perspectives

9.1. Summary of Etrasimod's Profile

Etrasimod (VELSIPITY™) has emerged as a significant addition to the therapeutic armamentarium for moderately to severely active ulcerative colitis. As an oral, once-daily, selective S1P1,4,5 receptor modulator, it offers a novel mechanism of action that involves the sequestration of lymphocytes in lymphoid organs, thereby reducing their migration to the inflamed intestinal mucosa. Clinical trial data from the ELEVATE UC program have robustly demonstrated its efficacy in inducing and maintaining clinical remission, endoscopic improvement, and mucosal healing in a challenging patient population, including those who have failed previous conventional or advanced therapies. The safety profile of etrasimod appears generally manageable, provided that appropriate pre-treatment screening and ongoing monitoring are diligently conducted.

9.2. Therapeutic Niche and Unmet Needs Addressed

Etrasimod addresses several unmet needs in UC management. It provides an effective oral treatment option, which is often preferred by patients over parenteral therapies, particularly for long-term management. Its efficacy in patients who have not responded to or tolerated other advanced therapies, including biologics and JAK inhibitors, positions it as a valuable later-line option. Furthermore, evidence suggesting its effectiveness as monotherapy and its potential for corticosteroid-sparing effects could simplify treatment regimens and reduce the burden of long-term steroid toxicity. By offering a distinct mechanism of action, etrasimod expands the range of choices for patients who may have exhausted other therapeutic avenues.

9.3. Ongoing Research and Potential Future Directions

The clinical development of etrasimod is ongoing. Long-term extension studies in UC continue to accrue data on sustained efficacy and safety, which will be crucial for understanding its long-term role.[30] Investigations in Crohn's disease through the CULTIVATE program are actively progressing and may expand its utility in IBD.[43] The positive Phase 2 results in eosinophilic esophagitis are promising and could lead to further development for this indication.[25] Conversely, the discontinuation of the alopecia areata program [42] and the mixed results in atopic dermatitis [41] help to define the boundaries of its therapeutic potential, emphasizing that S1P receptor modulation is not a universally effective strategy across all immune-mediated conditions.

Looking ahead, real-world evidence studies will be vital to confirm the effectiveness and safety of etrasimod in broader, more diverse patient populations encountered in routine clinical practice. Head-to-head comparative effectiveness research against other advanced therapies for UC would also provide invaluable insights to guide clinical decision-making and optimize treatment sequencing. The initial MAIC analysis comparing etrasimod to ozanimod is a step in this direction.[28]

Etrasimod represents a notable innovation in oral therapies for UC, offering convenience and a novel mechanism of action. However, its potent immunomodulatory effects necessitate a careful and informed approach to its use. This includes meticulous patient selection, strict adherence to pre-treatment screening and ongoing monitoring guidelines, and continued pharmacovigilance to fully delineate its long-term benefit-risk profile in real-world clinical settings. As etrasimod integrates into the dynamic and evolving landscape of IBD treatment, which includes a variety of biologics, other S1P modulators, and JAK inhibitors, its ultimate place will be shaped by long-term data on efficacy and safety, comparative effectiveness, patient and physician preferences, and pharmacoeconomic considerations.

Works cited

1. Etrasimod - Wikipedia, accessed June 5, 2025, https://en.wikipedia.org/wiki/Etrasimod
2. Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis, accessed June 5, 2025, https://www.mdpi.com/2077-0383/14/11/3890
3. Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis | Gastroenterología y Hepatología (English Edition) - Elsevier, accessed June 5, 2025, https://www.elsevier.es/en-revista-gastroenterologia-hepatologia-english-edition--382-articulo-etrasimod-review-efficacy-therapeutic-prospects-S2444382425000938
4. Etrasimod | C26H26F3NO3 | CID 44623998 - PubChem, accessed June 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Etrasimod
5. Etrasimod | APD334 | CAS# 1206123-37-6 | antagonist of the S1P1 | MedKoo, accessed June 5, 2025, https://www.medkoo.com/products/7089
6. Etrasimod: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 5, 2025, https://go.drugbank.com/drugs/DB14766
7. 216956Orig1s000 OTHER REVIEW(S) - accessdata.fda.gov, accessed June 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216956Orig1s000OtherR.pdf
8. Velsipity (etrasimod) FDA Approval History - Drugs.com, accessed June 5, 2025, https://www.drugs.com/history/velsipity.html
9. European Commission Approves Pfizer's VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis, accessed June 5, 2025, https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-velsipityr-patients
10. Getting a VELSIPITY® (etrasimod) Prescription for UC | Risk Info, accessed June 5, 2025, https://www.velsipity.com/starting-velsipity/getting-your-prescription
11. Etrasimod: First Approval - PubMed, accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/38388871/
12. etrasimod | CDA-AMC - Canada's Drug Agency, accessed June 5, 2025, https://www.cda-amc.ca/etrasimod
13. VELSIPITY™ Receives Health Canada Approval for Adults with Moderately to Severely Active Ulcerative Colitis (UC), accessed June 5, 2025, https://www.pfizer.ca/en/media-centre/velsipity-receives-health-canada-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-uc
14. Etrasimod (Velsipity) - NCBI Bookshelf, accessed June 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK607351/
15. Etrasimod approved to treat patients over the age of 16 with ulcerative colitis - GOV.UK, accessed June 5, 2025, https://www.gov.uk/government/news/etrasimod-approved-to-treat-patients-over-the-age-of-16-with-ulcerative-colitis--2
16. Velsipity | European Medicines Agency (EMA), accessed June 5, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity
17. Clinical Review - Etrasimod (Velsipity) - NCBI Bookshelf, accessed June 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK611318/
18. Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials - Frontiers, accessed June 5, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1420455/full
19. Summary report on authorisation – Velsipity® - Swissmedic, accessed June 5, 2025, https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-velsipity.html
20. Swissmedic - Summary report on authorisation – Velsipity - Public now, accessed June 5, 2025, https://www.publicnow.com/view/96A8317E325606EAEA6A8B72551D379EB27AE1A5?1737100028
21. Summary report on authorisation - Velsipity® (active substance: etrasimod) - Swissmedic, accessed June 5, 2025, https://www.swissmedic.ch/dam/swissmedic/en/dokumente/zulassung/swisspar-public/velsipity-wirkstoff-etrasimod.pdf.download.pdf/Kurzbericht%20Arzneimittelzulassung%20Velsipity%20ENG.pdf
22. Velsipity, INN-etrasimod arginine - European Medicines Agency, accessed June 5, 2025, https://www.ema.europa.eu/en/documents/product-information/velsipity-epar-product-information_en.pdf
23. VELSIPITY™ (etrasimod) Dosage and Administration | Pfizer ..., accessed June 5, 2025, https://www.pfizermedicalinformation.com/etrasimod/dosage-admin
24. UK MHRA grants marketing approval to Pfizer's etrasimod to treat patients over the age of 16 with ulcerative colitis - Pharmabiz.com, accessed June 5, 2025, https://www.pharmabiz.com/NewsDetails.aspx?aid=166931&sid=2
25. Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a ..., accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/40381637/
26. www.fda.gov, accessed June 5, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-velsipity#:~:text=The%20FDA%20approved%20VELSIPITY%20based,moderately%20to%20severely%20active%20UC.
27. Drug Trials Snapshots: VELSIPITY - FDA, accessed June 5, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-velsipity
28. Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis - Becaris Publishing, accessed June 5, 2025, https://becarispublishing.com/doi/pdf/10.57264/cer-2024-0193?download=true
29. Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9671063/
30. DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme - Oxford Academic, accessed June 5, 2025, https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i119/7966973
31. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme - PubMed, accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/38700040/
32. VELSIPITY Receives Health Canada Approval for Adults with Moderately to Severely Active Ulcerative Colitis (UC) - BioSpace, accessed June 5, 2025, https://www.biospace.com/velsipity-and-8482-receives-health-canada-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-uc
33. Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11417464/
34. Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program - PubMed, accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/39671695
35. Etrasimod for alopecia areata: The scenario for a less extensive and moderate form - PMC, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12105434/
36. Latest News - St Vincent's Hospital Sydney, accessed June 5, 2025, https://www.svhs.org.au/our-services/list-of-services/inflammatory-bowel-disease-service/latest-news
37. Etrasimod Arginine - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 5, 2025, https://synapse.patsnap.com/drug/037942429ddc424b962d7c7e779875db
38. Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program - Oxford Academic, accessed June 5, 2025, https://academic.oup.com/ecco-jcc/article/19/5/jjae173/7906855
39. Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program - PMC, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12087566/
40. Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients, accessed June 5, 2025, https://www.everestmedicines.com/news/everest-medicines-announces-the-first/f656ad8f-3a2d-4e82-add6-0889e22ac29a
41. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE) - PubMed, accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/36695074/
42. Efficacy and safety of etrasimod in alopecia areata: A multicentre ..., accessed June 5, 2025, https://pubmed.ncbi.nlm.nih.gov/40145547/
43. CULTIVATE: Promising signal for etrasimod in Crohn's disease - Medical Conferences, accessed June 5, 2025, https://conferences.medicom-publishers.com/content/conference-reports/cultivate-promising-signal-for-etrasimod-in-crohns-disease/
44. Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong, accessed June 5, 2025, https://www.everestmedicines.com/news/everest-medicines-announces-new-drug/9190f94f-5008-4c16-898a-28a1f4fa0d01